Outcomes and Therapeutic Management of Bladder Cancer

• Autres auteurs: Moschini, Marco (Éditeur intellectuel)
• Format: Électronique Chapitre de livre
• Langue: anglais
• Publié: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
• Sujets: Medicine; bladder cancer; robotic-assisted; open; radical cystectomy; survival; propensity score; age; urothelial carcinoma; outcome; anesthesia recovery periods; cognitive impairment; gamma-cyclodextrins; neuromuscular blockade; robotic radical cystectomy; glycogen; clear-cell adenocarcinoma; urinary bladder; SEER program database; female; intracorporeal neobladder; outcomes; robotic; sex-sparing; methylation; biomarkers; FOXA1; GATA3; KRT20; molecular markers; mRNA; muscle-invasive bladder cancer; PCR; human epidermal growth factor receptor 2; indoleamine 2,3-dioxygenase; programmed death ligand-1; immunotherapy; nodal disease; pN1; neoadjuvant; adjuvant; chemotherapy; n/a
• Accès en ligne: DOAB: download the publication; DOAB: description of the publication

Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invas...